Komori
Business alliance4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Notice of the Execution of an Exclusive License Agreement with Keio University for the Ophthalmic Drug "H-1129" for the Treatment of Corneal and Conjunctival Diseases

The Company has acquired the exclusive worldwide rights, including in Japan, to develop, manufacture, market and otherwise commercialize H-1129 under the jointly filed patent applications with Keio University. In consideration, the Company will pay an upfront fee, milestone fees based on development progress, and royalties after the product is marketed.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Exclusive license agreement
4576D.Western Therapeutics Institute, Inc.
Alliance partnerKeio University
Details of the alliance
  1. 1

    Acquisition of the exclusive rights to develop, manufacture, market and otherwise commercialize the product for the relevant indication worldwide, including in Japan

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

Impact on Business Performance

The Company believes that this agreement will contribute to increasing the value of its pipeline over the medium to long term.

Agreements reached under this partnership
ItemDetails
Name of alliance partnerKeio University
Type of allianceExclusive license agreement
Details of the allianceAcquisition of the exclusive rights to develop, manufacture, market and otherwise commercialize the product for the relevant indication worldwide, including in Japan
Impact on Business PerformanceThe Company believes that this agreement will contribute to increasing the value of its pipeline over the medium to long term.
Items this document does not state (19)
Alliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To make effective use of H-1129's intellectual property and pursue early commercialization. The Company also intends to expand into corneal and conjunctival diseases, where it may be able to take advantage of various incentives available under the Ministry of Health, Labour and Welfare's orphan drug designation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Execution of an Exclusive License Agreement with Keio University for the Ophthalmic Drug "H-1129" for the Treatment of Corneal and Conjunctival Diseases | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori